Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.
2.

Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder.

Lee MS, Yang JW, Ko YH, Han C, Kim SH, Lee MS, Joe SH, Jung IK.

Child Psychiatry Hum Dev. 2008 Jun;39(2):201-9. Epub 2007 Aug 31.

PMID:
17763937
3.

Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate.

Wang LJ, Hsiao CC, Huang YS, Chiang YL, Ree SC, Chen YC, Wu YW, Wu CC, Shang ZY, Chen CK.

Psychoneuroendocrinology. 2011 Sep;36(8):1209-16. doi: 10.1016/j.psyneuen.2011.02.014. Epub 2011 Mar 15.

PMID:
21411231
4.

Salivary neurosteroid levels and behavioural profiles of children with attention-deficit/hyperactivity disorder during six months of methylphenidate treatment.

Wang LJ, Wu CC, Lee SY, Tsai YF.

J Child Adolesc Psychopharmacol. 2014 Aug;24(6):336-40. doi: 10.1089/cap.2013.0122. Epub 2014 Jun 23.

PMID:
24956271
5.

Differential responses of two related neurosteroids to methylphenidate based on ADHD subtype and the presence of depressive symptomatology.

Molina-Carballo A, Justicia-Martínez F, Moreno-Madrid F, Cubero-Millán I, Machado-Casas I, Moreno-García L, León J, Luna-Del-Castillo JD, Uberos J, Muñoz-Hoyos A.

Psychopharmacology (Berl). 2014 Sep;231(17):3635-45. doi: 10.1007/s00213-014-3514-5. Epub 2014 Mar 6.

PMID:
24599397
6.

Analysis of neurosteroid levels in attention deficit hyperactivity disorder.

Strous RD, Spivak B, Yoran-Hegesh R, Maayan R, Averbuch E, Kotler M, Mester R, Weizman A.

Int J Neuropsychopharmacol. 2001 Sep;4(3):259-64.

PMID:
11602031
7.

An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.

Shang CY, Pan YL, Lin HY, Huang LW, Gau SS.

J Child Adolesc Psychopharmacol. 2015 Sep;25(7):566-73. doi: 10.1089/cap.2015.0035. Epub 2015 Jul 29.

PMID:
26222447
8.

Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.

Wang LJ, Chen CK, Huang YS.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):246-53. doi: 10.1089/cap.2014.0015. Epub 2015 Jan 9.

PMID:
25574708
9.

Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD).

Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, Najafi K, Atrkar Roushan Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:20-4. doi: 10.1016/j.pnpbp.2013.07.018. Epub 2013 Aug 8.

PMID:
23933054
10.
11.
12.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

PMID:
19165529
13.
15.
16.

Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.

Isaksson J, Hogmark Å, Nilsson KW, Lindblad F.

Psychiatry Res. 2013 Oct 30;209(3):740-1. doi: 10.1016/j.psychres.2013.06.011. Epub 2013 Jul 11.

PMID:
23850434
17.
18.

Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.

Buitelaar JK, Casas M, Philipsen A, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, van Oene JC, Schäuble B.

Psychol Med. 2012 Jan;42(1):195-204. doi: 10.1017/S0033291711000845. Epub 2011 Jun 1.

19.

Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.

Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):76-80. doi: 10.1016/j.pnpbp.2009.09.026. Epub 2009 Oct 5.

PMID:
19815048
20.

The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder.

Park S, Kim BN, Cho SC, Kim JW, Kim JI, Shin MS, Yoo HJ, Han DH, Cheong JH.

J Child Adolesc Psychopharmacol. 2014 May;24(4):223-7. doi: 10.1089/cap.2013.0079. Epub 2014 May 9.

PMID:
24815731

Supplemental Content

Support Center